CN110859883A - External-use tiger ginseng leaf essential oil for treating skin ulcer - Google Patents
External-use tiger ginseng leaf essential oil for treating skin ulcer Download PDFInfo
- Publication number
- CN110859883A CN110859883A CN201911306006.0A CN201911306006A CN110859883A CN 110859883 A CN110859883 A CN 110859883A CN 201911306006 A CN201911306006 A CN 201911306006A CN 110859883 A CN110859883 A CN 110859883A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- skin ulcer
- extraction
- treating skin
- mpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 171
- 206010040943 Skin Ulcer Diseases 0.000 title claims abstract description 46
- 231100000019 skin ulcer Toxicity 0.000 title claims abstract description 33
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 30
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 30
- 241000282376 Panthera tigris Species 0.000 title claims abstract description 30
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 30
- 241000208340 Araliaceae Species 0.000 title claims 5
- 239000003814 drug Substances 0.000 claims abstract description 22
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 18
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 18
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 17
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 17
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 17
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 16
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 16
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 16
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 16
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 16
- 241000246044 Sophora flavescens Species 0.000 claims abstract description 16
- 235000017276 Salvia Nutrition 0.000 claims abstract description 15
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 15
- 241000972672 Phellodendron Species 0.000 claims abstract description 12
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 10
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940116229 borneol Drugs 0.000 claims abstract description 10
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 10
- 235000011477 liquorice Nutrition 0.000 claims abstract description 10
- 238000000605 extraction Methods 0.000 claims description 73
- 238000000926 separation method Methods 0.000 claims description 42
- 239000007788 liquid Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 22
- 239000012530 fluid Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 17
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 15
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 3
- 244000301850 Cupressus sempervirens Species 0.000 claims 1
- 240000001341 Reynoutria japonica Species 0.000 abstract description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 240000004371 Panax ginseng Species 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 208000025865 Ulcer Diseases 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010063560 Excessive granulation tissue Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 210000001126 granulation tissue Anatomy 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 6
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940010454 licorice Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000007873 sieving Methods 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 244000288377 Saxifraga stolonifera Species 0.000 description 3
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229940010073 hydrocortisone injection Drugs 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000798474 Taxodium distichum var. distichum Species 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 206010044546 Traumatic ulcer Diseases 0.000 description 1
- 206010050283 Tumour ulceration Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000000658 coextraction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/025—Recovery by solvent extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to external-use tiger ginseng leaf essential oil for treating skin ulcer, which can effectively solve the problem of medicament application for treating skin ulcer and adopts the technical scheme that the external-use tiger ginseng leaf essential oil comprises the following components: 2.5-3.5mL of phellodendron essential oil, 2.5-3.5mL of myrrh essential oil, 4-6mL of safflower essential oil, 4-6mL of salvia essential oil, 6-8mL of polygonum cuspidatum essential oil, 6-8mL of sophora flavescens essential oil, 4-6mL of angelica essential oil, 5-7mL of cassia twig essential oil, 7-9mL of cacumen biotae, 6-8mL of liquorice essential oil and 9-11g of borneol are dissolved and uniformly mixed to prepare the traditional Chinese medicine.
Description
Technical Field
The invention relates to a medicine, in particular to an external-use tiger ginseng leaf essential oil for treating skin ulcer.
Background
Skin ulcer is a common and frequently-occurring disease in surgery of traditional Chinese medicine, is a body surface disease which is characterized in that skin ulcer is taken as a main clinical manifestation and can not be healed for a long time and skin tissue defect is liquefied, infected and necrotic, and is generally a long-term unhealed patient after ulcer of skin ulcer in surgery of traditional Chinese medicine. Because the sore surface is difficult to heal and the consumption is very large, great psychological pressure and economic loss are caused to the patient, and the physical health and the life quality of the patient are seriously influenced.
Skin ulcer is limited skin tissue defect caused by traumatic microorganism infection, tumor circulation disorder and nerve dysfunction, immune dysfunction or congenital skin defect, traumatic ulcer is usually caused by physical and chemical factors directly acting on tissues, microbial infectious diseases are mostly caused by tissue destruction, nodule or tumor ulceration caused by bacteria, fungal spirochetes, viruses and the like, vascular inflammatory ulcer system caused by immune dysfunction is formed by necrosis of tissues caused by artery or arteriolar inflammation, circulation or nerve dysfunction belongs to the genus of nutrition disorder is caused by tissue necrosis, such as varicose leprosy ulcer and the like.
At present, although there are many drugs for treating skin ulcer, such as antiallergic drugs, antiparasitic drugs, antibiotics, and drugs for promoting ulcer healing, their use and efficacy are not satisfactory for various reasons, so how to effectively treat skin ulcer is a technical problem of interest in the industry.
Disclosure of Invention
Aiming at the situation, in order to overcome the defects of the prior art, the invention aims to provide the tiger ginseng leaf essential oil for treating skin ulcer by external application, which can effectively solve the problem of medicament for treating skin ulcer.
The technical scheme for solving the problem is that the external-use tiger ginseng leaf essential oil for treating skin ulcer comprises the following components: 2.5-3.5mL of phellodendron essential oil, 2.5-3.5mL of myrrh essential oil, 4-6mL of safflower essential oil, 4-6mL of salvia essential oil, 6-8mL of giant knotweed essential oil, 6-8mL of sophora flavescens essential oil, 4-6mL of angelica essential oil, 5-7mL of cassia twig essential oil, 7-9mL of cacumen biotae, 6-8mL of liquorice essential oil and 9-11g of borneol are dissolved and uniformly mixed to prepare the traditional Chinese medicine, wherein:
the cortex phellodendri essential oil is prepared by crushing cortex phellodendri into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the weight-volume ratio refers to that the solid is measured in g, the liquid is measured in mL (the same below), the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the phellodendron essential oil is obtained;
the myrrh essential oil is prepared by crushing myrrh, sieving with a sieve of 10-20 meshes and performing supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that myrrh essential oil is obtained;
the safflower essential oil is prepared by crushing safflower into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain safflower essential oil;
the salvia essential oil is prepared by crushing salvia into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting with a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the salvia essential oil;
the giant knotweed essential oil is prepared by crushing giant knotweed into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain giant knotweed essential oil;
the sophora flavescens essential oil is prepared by crushing sophora flavescens into 10-20 mesh coarse powder and performing supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the sophora flavescens essential oil;
the angelica essential oil is prepared by crushing angelica, sieving with a sieve of 10-20 meshes and carrying out supercritical CO extraction2Extracting with a liquid material in a weight-volume ratio of 1: 10-20Taking the angelica essential oil, wherein the temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the angelica essential oil is obtained;
the cassia twig essential oil is prepared by crushing cassia twigs into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting with a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the cassia twig essential oil;
the cacumen biotae essential oil is prepared by crushing cacumen biotae into coarse powder which is sieved by a sieve of 10-20 meshes and performing supercritical CO treatment2Extracting with a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the cacumen biotae essential oil;
the licorice essential oil is prepared by crushing licorice into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2And (3) fluid extraction, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the licorice essential oil is obtained.
The invention has the advantages of rich raw materials, simple preparation method, easy production and preparation, convenient use and good effect, has the function of improving skin ulcer, is an innovation on the medicine for treating skin ulcer, and has remarkable economic and social benefits.
Detailed Description
The following examples are provided to explain the present invention in detail.
The invention may be embodied in the form of the following examples.
Example 1
The invention relates to a tiger ginseng leaf essential oil for treating skin ulcer, which comprises the following components: 3mL of phellodendron essential oil, 3mL of myrrh essential oil, 5mL of safflower essential oil, 5mL of salvia essential oil, 7mL of giant knotweed essential oil, 7mL of sophora flavescens essential oil, 5mL of angelica essential oil, 6mL of cassia twig essential oil, 8mL of cacumen biotae, 7mL of liquorice essential oil and 10g of borneol are dissolved and uniformly mixed to prepare the traditional Chinese medicine, wherein:
said yellowCypress essential oil is prepared by pulverizing cortex Phellodendri into coarse powder, sieving with 10-20 mesh sieve, and supercritical CO2Extracting a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the weight-volume ratio refers to that the solid is measured in g, the liquid is measured in mL (the same below), the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the phellodendron essential oil is obtained;
the myrrh essential oil is prepared by crushing myrrh, sieving with a sieve of 10-20 meshes and performing supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that myrrh essential oil is obtained;
the safflower essential oil is prepared by crushing safflower into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain safflower essential oil;
the salvia essential oil is prepared by crushing salvia into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting with a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the salvia essential oil;
the giant knotweed essential oil is prepared by crushing giant knotweed into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain giant knotweed essential oil;
the sophora flavescens essential oil is prepared by crushing sophora flavescens into 10-20 mesh coarse powder and performing supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the sophora flavescens essential oil;
the angelica essential oil is prepared by crushing angelica and sieving the crushed angelica with 10-20 meshesSieving, supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the angelica essential oil is obtained;
the cassia twig essential oil is prepared by crushing cassia twigs into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting with a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the cassia twig essential oil;
the cacumen biotae essential oil is prepared by crushing cacumen biotae into coarse powder which is sieved by a sieve of 10-20 meshes and performing supercritical CO treatment2Extracting with a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the cacumen biotae essential oil;
the licorice essential oil is prepared by crushing licorice into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2And (3) fluid extraction, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the licorice essential oil is obtained.
Example 2
The invention relates to a tiger ginseng leaf essential oil for treating skin ulcer, which comprises the following components: 2.8mL of phellodendron essential oil, 3.3mL of myrrh essential oil, 4.5mL of safflower essential oil, 5.5mL of salvia essential oil, 6.5mL of giant knotweed essential oil, 7.5mL of sophora flavescens essential oil, 4.5mL of angelica essential oil, 6.5mL of cassia twig essential oil, 7.5mL of cacumen biotae, 7.5mL of liquorice essential oil and 9.5g of borneol are dissolved and mixed uniformly to prepare the traditional Chinese medicine composition, and the preparation method is the same as that of example 1.
Example 3
The invention relates to a tiger ginseng leaf essential oil for treating skin ulcer, which comprises the following components: 3.3mL of phellodendron essential oil, 2.8mL of myrrh essential oil, 5.5mL of safflower essential oil, 4.5mL of salvia miltiorrhiza essential oil, 7.5mL of giant knotweed essential oil, 6.5mL of sophora flavescens essential oil, 5.5mL of angelica essential oil, 5.5mL of cassia twig essential oil, 8.5mL of cacumen biotae, 6.5mL of liquorice essential oil and 10.5g of borneol are dissolved and mixed uniformly to prepare the traditional Chinese medicine composition, and the preparation method is the same as that of example 1.
The recipe treats skin ulcer caused by heat-toxin accumulation and qi stagnation and blood stasis, and has the characteristics of blood stasis, toxin and heat. In the formula, the arborvitae tops are bitter and cold and enter lung meridian, and are mainly used for cooling blood and stopping bleeding; cortex Phellodendri and radix Sophorae Flavescentis are bitter and cold, and can be used together for clearing heat, eliminating dampness, clearing pathogenic fire, removing toxic substance and healing sore, and can be used for treating pyocutaneous disease, toxic swelling and skin pruritus; adding radix Angelicae sinensis, Saviae Miltiorrhizae radix, Carthami flos, and Myrrha, promoting qi and blood circulation, dredging collaterals, and relieving swelling and pain; at the beginning of the sore, the pathogenic factors are mostly remained between the skin and the skin striae, and the pungent and dispersing cassia twig is used to coordinate with each other to dredge and disperse the stagnation, so that the heat-toxin is released from the outside; polygonum cuspidatum enters blood system, has the functions of cooling blood, clearing heat and removing toxicity, and has better curative effect on yellow water flowing after ulceration when being used together with borneol; licorice root, radix Glycyrrhizae clears away heat and toxic materials, and coordinates the effects of the other drugs in the recipe. The medicines are combined to play the roles of clearing heat and removing toxicity, activating blood and relieving pain, eliminating dampness and healing sores.
The invention has scientific and reasonable compatibility and mutual support of components, has the effect of improving skin ulcer, is effectively used for treating skin ulcer, has very good experimental effect and has the following relevant data:
firstly, animal experiments:
1 materials of the experiment
1.1 medicine
The product of example 1 of the invention.
1.2 reagents and apparatus
Hydrocortisone injection, Elisa kit, Jinzhen peptide, Shenzhen Huasheng Yuangen engineering development Limited batch number: s 20010038;
electronic balance of FA (N)/JA (N) series, Shanghai Minqiao precision instruments, Inc.; KDC-160HR high speed refrigerated centrifuge, a good division of the science Innovation Co., Ltd; model 680 enzyme calibrator, BIO-RAD, USA; adjustable pipettes, shanghai leibo analytical instruments ltd.
1.3 animals
18-22 g mouse male germ line: BALB/c rating: SPF stage
Central quality certification of experimental animals in Shandong province: NO.37009200017346
Experimental methods
60 SPF-grade BALB/c mice are selected, and the male mice are 18-21 g in weight. In the laboratoryAfter being normally bred for 3 days, the breeding animals are respectively randomly divided into 5 groups, namely a blank group, a model group, a positive group and a tiger ginseng essential oil size dose group, wherein each group contains 12 animals. Except for the blank group, 4mL/kg of hydrocortisone injection (5 g/L) is continuously injected into the thigh of each group of mice for 5d, each group of mice is anesthetized with 0.03mL of 10% chloral hydrate on the 6 th day, the back hairs are cut off, after the mice are sterilized by iodine tincture and 75% ethanol solution, part of the skin is cut off to form a square skin full-layer incision with the length of about 1cm, and after 24h, the mouse yin syndrome pyocutaneous disease model is successfully prepared. The model making method is used for preparing a mouse model with chronic skin ulcer, and blank mice are only subjected to a dummy operation. The high-dose component of the tiger ginseng essential oil is coated with 0.3ml/cm of tiger ginseng essential oil on the part of a model2Coating 0.15ml/cm2After 1 hour, the mixture is coated again with 0.15ml/cm2(ii) a The small dosage of the radix Saussureae Cordifoliae essential oil is applied to the part of the model with 0.15ml/cm of the radix Saussureae Cordifoliae essential oil2(ii) a Positive group, treatment was administered for 14 days. And (4) observing pathological results, wherein the appearance indexes are as follows: motility, area of sore surface, secretion from sore surface, etc. It is manifested as clear and thin secretion on the sore surface, dark and unsmooth granulation, loose stool, crouching, cold tail, and reduced movement of healthy qi. Pathological indexes are that the skin of the wound surface is taken after the test is finished, fixed by 10 percent formaldehyde, sliced and examined under the microscope. The skin at the ulcer homogenizes the EGF and BFGF levels.
3. The experimental results are as follows:
3.1 Effect on appearance index of mouse model of chronic skin ulcer
The appearance of the mouse model of chronic skin ulcer mainly means that secretion, secretion color, swelling and the like exist on the sore surface, and the appearance is respectively counted for 0, 1, 2 and 3 points according to the condition of no, light, heavy and heavy.
TABLE 1 Effect of Saxifraga stolonifera essential oil on the score of skin and external diseases of mouse chronic skin ulcer model: (
±s）
| Group of | N | Integration |
| Blank group | 12 | 0.00±0.00** |
| Model set | 12 | 2.67±0.49 |
| Group of jinyin peptides | 12 | 1.45±0.52** |
| High-dose component of tiger ginseng essential oil | 12 | 2.22±0.51* |
| Small-dose group of tiger ginseng essential oil | 12 | 2.15±0.42** |
P <0.05, P <0.01, compared to model group
As can be seen from the above table, the local integral of skin ulcer in the model group mice was significantly increased (P < 0.01) compared to the blank group. Compared with the model group, the small-dose group of the tiger ginseng essential oil and the jin-yin peptide group can obviously reduce the skin ulcer integral of the mouse (P is less than 0.01), and the large-dose group of the tiger ginseng essential oil can obviously reduce the skin ulcer integral of the mouse (P is less than 0.01).
3.2. Influence on local biochemical indexes of chronic skin ulcer model ulcer of mice
TABLE 2 Effect of Saxifraga stolonifera essential oil on mouse Chronic skin ulcer model ulcer local homogenate BFGF and VEGF level ((
±s）
| Group of | N | BFGF（µg/ml） | VEGF（µg/ml） |
| Blank group | 12 | 57.84±4.23** | 230.5±31.27** |
| Model set | 12 | 52.63±2.85 | 180.01±31.87 |
| Group of jinyin peptides | 12 | 54.65±5.30 | 201.92±42.18 |
| High-dose component of tiger ginseng essential oil | 12 | 56.11±3.60** | 197.52±41.46 |
| Small-dose group of tiger ginseng essential oil | 12 | 53.49±2.94 | 188.85±35.19 |
P <0.05, P <0.01, compared to model group
As can be seen from the table above, compared with the blank group, the skin homogenate BFGF and VEGF level of the model group local skin homogenate model mouse are obviously reduced (P is less than 0.01); compared with the model group, the tiger-ginseng essential oil large-dose group can obviously increase the BFGF level in the skin homogenate of the mouse chronic skin ulcer model (P is less than 0.05), and the tiger-ginseng essential oil small-dose group and the jin-yin peptide group have the tendency of increasing the BFGF level in the local skin homogenate (P is more than 0.05); the large and small dose groups of the tiger ginseng essential oil and the chrysin peptide group have a tendency to increase the VEGF level in local skin homogenates (P > 0.05).
3.3. Influence on local tissue morphology of ulcer of mouse chronic skin ulcer model
The blank group of mice has complete skin tissue structure, clear layers and abundant hair follicles and sweat glands; the epidermis of the model group is thickened locally, and the tissues have extensive granulation tissues and inflammatory cell infiltration; the skin epidermis of the local skin of the aureopeptide group is thickened, a small amount of granulation tissues can be seen in the tissues, and a small amount of inflammatory cells are infiltrated; the epidermis of the large-dose group of the tiger ginseng essential oil is thickened locally, a large amount of granulation tissues can be filled in the tissues, and a small amount of inflammatory cells are infiltrated; the local epidermis of the small-dose group of the tiger ginseng essential oil is thickened, a large amount of granulation tissues can be filled in the tissues, and a small amount of inflammatory cells are infiltrated.
TABLE 3 influence of the essential oil of Saxifraga stolonifera on the local tissue morphology of ulcer in mouse model of chronic skin ulcer: (
±s）
| Group of | N | - | + | ++ | +++ | P |
| Blank group | 12 | 12 | 0 | 0 | 0 | ** |
| Model set | 12 | 0 | 0 | 2 | 10 | |
| Group of jinyin peptides | 12 | 0 | 2 | 7 | 3 | ** |
| High-dose component of tiger ginseng essential oil | 12 | 0 | 3 | 7 | 2 | ** |
| Small-dose group of tiger ginseng essential oil | 12 | 0 | 2 | 7 | 3 | ** |
"-" skin tissue structure is complete, level is clear; the "+" tissue showed a small amount of granulation tissue and a small amount of inflammatory cell infiltration; the "+" tissue was filled with a large amount of granulation tissue and infiltrated with a small amount of inflammatory cells; the epidermis was thickened and the subcutaneous tissue was extensively infiltrated with granulation tissue and inflammatory cells.
As can be seen from the above table, compared with the blank group, the morphology of the local skin tissue of the model group shows significant pathological changes (P < 0.01); compared with the model group, the large and small dose groups of the tiger ginseng essential oil and the chrysopeptide group can obviously relieve the pathological changes of local skin (P is less than 0.01).
Second, clinical application
Under the condition of ensuring safety in animal experiments, clinical trials prove that the effect is very good, and the related data are as follows (taking example 1 as an example):
the skin ulcer is a body surface disease which is characterized by clinical manifestation of skin ulcer and long-term failure of healing, and skin tissue defect liquefaction, infection and necrosis are often called as chronic skin ulcer.
16 clinically diagnosed patients with chronic skin ulcer, wherein 12 male patients and 4 female patients are aged 16-56 years and the course of the disease is 1-24 months.
The application method comprises the following steps: firstly, for the patientThe ulcer part is debrided, the wound surface is disinfected conventionally, and then the essential oil of the tiger ginseng leaf is directly coated on the wound surface, 0.15mL/cm2. Applied 2 times daily for 2 months.
Criteria for efficacy assessment
And (3) healing: the wound surface is healed, and clinical symptoms disappear; the effect is shown: the wound surface is reduced by 75%, and clinical symptoms disappear; and (4) invalidation: the wound surface is reduced by less than 25%, and the clinical symptoms are not improved.
Statistical treatment:
after the essential oil is adopted for treatment for 2 months according to the treatment scheme, the results are as follows through statistical treatment:
16 patients with chronic skin ulcer are cured by 10 patients (62.5%), 4 patients with obvious effect (25%), 2 patients with no effect (12.5%), and the total effective rate is 87.5%, thus achieving satisfactory technical effect.
The same experiment is carried out on the example 1 and the examples 2 and 3 at the same time, and the same and similar results are obtained, which shows that the product has good quality and stable and reliable curative effect, and are not listed any more.
The experiments show that the traditional Chinese medicine composition has the function of improving skin ulcer, is effectively used for treating chronic skin ulcer, has simple preparation method, rich raw materials, easy production and preparation and definite curative effect, is an innovation on the medicine for treating skin ulcer, and has obvious economic and social benefits.
Claims (4)
1. The external-use tiger ginseng leaf essential oil for treating skin ulcer is characterized by comprising the following components: 2.5-3.5mL of phellodendron essential oil, 2.5-3.5mL of myrrh essential oil, 4-6mL of safflower essential oil, 4-6mL of salvia essential oil, 6-8mL of giant knotweed essential oil, 6-8mL of sophora flavescens essential oil, 4-6mL of angelica essential oil, 5-7mL of cassia twig essential oil, 7-9mL of cacumen biotae, 6-8mL of liquorice essential oil and 9-11g of borneol are dissolved and uniformly mixed to prepare the traditional Chinese medicine, wherein:
the cortex phellodendri essential oil is prepared by crushing cortex phellodendri into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting fluid, wherein the weight volume ratio of liquid to material is 1: 10-20, the weight volume ratio refers to that the solid is counted by g, the liquid is counted by mL, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, and the separation pressure isThe force is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the phellodendron essential oil is obtained;
the preparation methods of the myrrh essential oil, the safflower essential oil, the salvia essential oil, the giant knotweed essential oil, the sophora flavescens essential oil, the angelica essential oil, the cassia twig essential oil, the cacumen biotae and the liquorice essential oil are the same as the golden cypress essential oil.
2. The essential oil of tiger ginseng leaf for external use for treating skin ulcer as claimed in claim 1, which is prepared from the following components: 3mL of phellodendron essential oil, 3mL of myrrh essential oil, 5mL of safflower essential oil, 5mL of salvia essential oil, 7mL of giant knotweed essential oil, 7mL of sophora flavescens essential oil, 5mL of angelica essential oil, 6mL of cassia twig essential oil, 8mL of cacumen biotae, 7mL of liquorice essential oil and 10g of borneol are dissolved and mixed uniformly to prepare the traditional Chinese medicine.
3. The essential oil of tiger ginseng leaf for external use for treating skin ulcer as claimed in claim 1, which is prepared from the following components: 2.8mL of phellodendron essential oil, 3.3mL of myrrh essential oil, 4.5mL of safflower essential oil, 5.5mL of salvia essential oil, 6.5mL of giant knotweed essential oil, 7.5mL of sophora flavescens essential oil, 4.5mL of angelica essential oil, 6.5mL of cassia twig essential oil, 7.5mL of cacumen biotae, 7.5mL of liquorice essential oil and 9.5g of borneol are dissolved and mixed uniformly to prepare the traditional Chinese medicine.
4. The essential oil of tiger ginseng leaf for external use for treating skin ulcer as claimed in claim 1, which is prepared from the following components: 3.3mL of phellodendron essential oil, 2.8mL of myrrh essential oil, 5.5mL of safflower essential oil, 4.5mL of salvia essential oil, 7.5mL of giant knotweed essential oil, 6.5mL of sophora flavescens essential oil, 5.5mL of angelica essential oil, 5.5mL of cassia twig essential oil, 8.5mL of cacumen biotae, 6.5mL of liquorice essential oil and 10.5g of borneol are dissolved and mixed uniformly to prepare the traditional Chinese medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911306006.0A CN110859883A (en) | 2019-12-18 | 2019-12-18 | External-use tiger ginseng leaf essential oil for treating skin ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911306006.0A CN110859883A (en) | 2019-12-18 | 2019-12-18 | External-use tiger ginseng leaf essential oil for treating skin ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110859883A true CN110859883A (en) | 2020-03-06 |
Family
ID=69659020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911306006.0A Pending CN110859883A (en) | 2019-12-18 | 2019-12-18 | External-use tiger ginseng leaf essential oil for treating skin ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110859883A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089494A (en) * | 1993-01-06 | 1994-07-20 | 张萍 | Ointment for growing muscle and healing skin |
| CN1159940A (en) * | 1997-01-15 | 1997-09-24 | 张萍 | Composition for promoting muscle growing and skin healing and preparing method thereof |
| CN101721527A (en) * | 2009-09-29 | 2010-06-09 | 温志亭 | Traditional Chinese medicine jewelry cream and preparation method thereof |
| CN103720862A (en) * | 2012-10-12 | 2014-04-16 | 丁小燕 | Sophora flavescens health-care wine for controlling lower limb chronic ulcer |
| CN109125474A (en) * | 2018-10-15 | 2019-01-04 | 河南中医药大学 | A kind of silver yellow ginseng essential oil for treating solar dermatitis |
-
2019
- 2019-12-18 CN CN201911306006.0A patent/CN110859883A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089494A (en) * | 1993-01-06 | 1994-07-20 | 张萍 | Ointment for growing muscle and healing skin |
| CN1159940A (en) * | 1997-01-15 | 1997-09-24 | 张萍 | Composition for promoting muscle growing and skin healing and preparing method thereof |
| CN101721527A (en) * | 2009-09-29 | 2010-06-09 | 温志亭 | Traditional Chinese medicine jewelry cream and preparation method thereof |
| CN103720862A (en) * | 2012-10-12 | 2014-04-16 | 丁小燕 | Sophora flavescens health-care wine for controlling lower limb chronic ulcer |
| CN109125474A (en) * | 2018-10-15 | 2019-01-04 | 河南中医药大学 | A kind of silver yellow ginseng essential oil for treating solar dermatitis |
Non-Patent Citations (3)
| Title |
|---|
| 史岚峰: "复方虎杖敛疮液治疗慢性难愈性溃疡及压疮160例的护理", 《河北中医》 * |
| 黄红: "斯奇康联合消银颗粒治疗银屑病疗效观察", 《中国误诊学杂志》 * |
| 黄黎明等: "复方白及涂膜剂治疗大鼠烧烫伤实验研究", 《中国中医药信息杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091203B (en) | External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof | |
| CN1315525C (en) | Chinese traditional medicine for treating breast disease and preparing technique | |
| CN103230493B (en) | Traditional Chinese medicine composition for treating unhealed wound | |
| CN102415988B (en) | Wound healing gel and preparation process thereof | |
| CN104940627A (en) | Traditional Chinese medicine composition for promoting wound healing, and preparation method of traditional Chinese medicine composition | |
| CN109549958B (en) | Composition for treating hormone-dependent dermatitis and preparation method thereof | |
| CN103432419A (en) | Traditional Chinese medicinal composition for treating dysfunctional uterine bleeding and preparation method of preparation thereof | |
| CN105194270A (en) | Traditional Chinese medicine ointment for treating skin diseases | |
| CN110859883A (en) | External-use tiger ginseng leaf essential oil for treating skin ulcer | |
| CN101332286B (en) | Traditional Chinese medicine composition for treating skin disease and preparation method thereof | |
| CN109432203B (en) | Pharmaceutical composition and traditional Chinese medicine raw material composition for treating non-lactation mastitis | |
| CN104623443A (en) | Traditional Chinese medicine for treating skin erosion | |
| CN102813811B (en) | External paste used for promoting postoperation wound healing of caesarean delivery | |
| CN111298053A (en) | Bezoar dragon bone ointment for treating hemorrhoid | |
| CN105853866A (en) | Method for preparing Chinese herbal medicine composition for treating bedsore | |
| CN108815268A (en) | A kind of external application promotees the Chinese medicine ointment formulation and preparation method thereof of union of wounded skin | |
| CN103989771A (en) | Pearl powder scald ointment | |
| CN116115687B (en) | Traditional Chinese medicine composition for gout and preparation method and application thereof | |
| CN103599253B (en) | Traditional Chinese medicine composition for treating winter pruritus of old people | |
| CN110882270B (en) | Pharmaceutical composition containing silicon-based regenerative medical material and preparation method thereof | |
| CN102302703B (en) | Medicament for treating chloasma | |
| CN101983681A (en) | Medicament for treating abnormal leucorrhea | |
| CN107050298A (en) | A kind of Chinese medicine paste formulation and preparation method for treating burn and scald skin damaged | |
| CN105213732A (en) | A kind of band bed sore ointment and preparation method thereof | |
| CN1243558C (en) | External use medicine for treating bone ulcer and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200306 |
|
| RJ01 | Rejection of invention patent application after publication |